Current Oncology is a prominent open-access journal dedicated to the field of oncology, published by MDPI in Switzerland. With an ISSN of 1198-0052 and E-ISSN 1718-7729, this esteemed journal has been providing valuable insights since its inception in 1998 and continues to publish cutting-edge research through 2024. Recognized for its contribution to the medical community, Current Oncology holds a 2023 Q2 category rank in Oncology and is positioned at the 41st percentile among its peers in Scopus rankings. As a hub for innovation and discussion in cancer research, it offers a plethora of articles that span various aspects of oncology, making it an essential resource for researchers, professionals, and students alike. Since becoming fully open-access in 2006, it provides expanded accessibility to groundbreaking studies and findings, fostering collaboration and knowledge exchange across the global research community. With its central location in Basel, Switzerland, Current Oncology plays a pivotal role in advancing oncology's frontiers.

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, published by Wiley, is a leading journal in the field of obstetrics and gynecology that has been disseminating high-quality research since its inception. With an ISSN of 1341-8076 and an E-ISSN of 1447-0756, this journal thrives on contributing to this specialized area of medicine, showcasing innovations and advancements essential for practitioners and scholars alike. Notably, it holds a commendable Impact Factor reflective of its Q2 ranking in both Medicine and Obstetrics and Gynecology categories for 2023, placing it in the 55th percentile among its peers according to Scopus. The journal covers a wide array of topics pertinent to contemporary medical practices and research in Australia and beyond, aiming to foster interdisciplinary dialogue and advance clinical practices. Researchers, professionals, and students will find it an invaluable resource, featuring rigorous peer-reviewed articles that shed light on emerging trends, clinical guidelines, and groundbreaking studies. As it continues to converge on pivotal medical issues up until 2024, JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH stands poised to make a lasting impact in the realm of women's health.

Welcome to the International Journal of Biological Markers, a distinguished publication under SAGE Publications Ltd that has been a vital resource in the fields of Cancer Research, Clinical Biochemistry, Oncology, and Pathology and Forensic Medicine since its inception in 1986. With a commitment to disseminating high-quality research, the journal enjoys a robust impact highlighted by its Q2 and Q3 rankings across multiple categories in 2023, as evidenced by its Scopus rankings placing it in respectable percentiles. Based in Italy, this journal serves a global audience of researchers, clinicians, and students eager to keep abreast of the latest discoveries involving biological markers and their applications in medicine. Emphasizing rigorous peer review and scholarly integrity, the International Journal of Biological Markers plays a crucial role in advancing knowledge that can significantly impact clinical practices and enhance patient care.

GEBURTSHILFE UND FRAUENHEILKUNDE is a prestigious journal dedicated to the fields of Maternity, Midwifery, Obstetrics, and Gynecology, published by GEORG THIEME VERLAG KG, a reputable publisher known for its commitment to advancing medical knowledge. Established in 1947, the journal has consistently provided a platform for high-quality research and clinical studies that address current challenges and innovations in women's health. With an impact factor positioned in Q2 for Maternity and Midwifery and Q3 in Obstetrics and Gynecology, it ranks among the top journals within its field, further solidified by its Scopus rankings highlighting its influential presence. Although the journal is not open access, it remains an essential resource for academics and practitioners keen to stay informed on the latest evidence-based practices and cutting-edge research, ensuring that all stakeholders in women's healthcare can access critical insights to enhance patient outcomes.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.

The Journal of the Turkish-German Gynecological Association, published by GALENOS PUBL HOUSE, stands as a significant contribution to the field of obstetrics and gynecology, fostering a vital dialogue between Turkish and German medical communities since its establishment. This peer-reviewed, Open Access journal, which has been accessible since 2000, provides a platform for the dissemination of cutting-edge research, clinical practices, and reviews that are pivotal for advancing women's health. With a current impact factor correlation reflecting its status within the Q3 category in the obstetrics and gynecology domain, the journal is ranked #108 out of 209 in Scopus, placing it in the 48th percentile for its field. Covering a broad range of topics from innovative treatment methods to emerging technologies in gynecology, this journal is dedicated to enriching the academic landscape and providing healthcare professionals, researchers, and students with valuable insights and knowledge essential for improving patient outcomes. The journal’s headquarters in Turkey underscores its commitment to enriching local and international discourse in women's health.

Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

Middle East Journal of Cancer, with an ISSN of 2008-6709 and an E-ISSN of 2008-6687, is a prominent open-access journal published by Shiraz University of Medical Sciences since 2010. Based in Iran, the journal aims to advance the knowledge and understanding of cancer research and oncology through the dissemination of high-quality, peer-reviewed articles. With open access availability, it promotes global collaboration and accessibility in research, making findings readily available to a wider audience. The journal is categorized in Q4 for both Cancer Research and Oncology as of 2023, highlighting its emerging presence in these fields. Alongside its Scopus ranks, where it positions 319th out of 404 in Medicine - Oncology and 198th out of 230 in Biochemistry, Genetics and Molecular Biology - Cancer Research, it serves as a platform for researchers, professionals, and students to enrich their expertise and contribute to the evolving landscape of cancer studies. The journal's continuous commitment to quality and accessibility represents an essential resource for those dedicated to advancing cancer research and improving patient outcomes in the Middle East and beyond.